NextCure, Inc.
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including antibody-drug conjugates (ADCs), for patients whose disease does not respond to or progresses on existing treatments. Its lead candidates are SIM0505, a CDH6-targeted ADC using a topoisomerase 1… From the company’s description.
In fiscal 2025, NextCure, Inc. reported a net loss of $55.84M. Operations used $49.61M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NextCure, Inc. does
In the company’s own words
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including antibody-drug conjugates (ADCs), for patients whose disease does not respond to or progresses on existing treatments. Its lead candidates are SIM0505, a CDH6-targeted ADC using a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-targeted ADC using a tubulin inhibitor payload; both are in Phase 1 clinical development for solid tumors. NextCure advances LNCB74 with LigaChem Biosciences, sharing development costs and any commercial profits equally, and licenses SIM0505 and ADC technology from Simcere Zaiming, which retains rights in China, Hong Kong, Macau and Taiwan. The company also has oncology candidates NC410 and NC525 and preclinical programs NC181 for Alzheimer’s disease and NC605 for bone disorders, which it seeks to partner or finance. Its manufacturing facility has 2,000 liters of production capacity, though internal operations are paused.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BALTIMORE, MD
- Fiscal year end
- December
- CIK
- 1661059
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NextCure, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NextCure, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NextCure, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NextCure, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NextCure, Inc.'s last four quarterly filings that the numbers alone won't show?”